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1. INTRODUCTION {#cas14199-sec-0001}
===============

In clinical practice, a biopsy is of paramount importance for the identification of lung tumor histology and its stage confirmation.[1](#cas14199-bib-0001){ref-type="ref"} Currently, tissue biopsy, an invasive and time‐consuming procedure, is often relied upon for confirmation of lung cancer, yet access to tissue samples is often limited due to the anatomical location of the tumors.[2](#cas14199-bib-0002){ref-type="ref"}, [3](#cas14199-bib-0003){ref-type="ref"}, [4](#cas14199-bib-0004){ref-type="ref"} Further, to understand tumor progression and the initial response to treatment, re‐biopsy is often required; yet, the information obtained is often confounded by heterogeneity among the primary tumor and secondary metastases, thus limiting a clear representation of the disease profile.[5](#cas14199-bib-0005){ref-type="ref"}, [6](#cas14199-bib-0006){ref-type="ref"} Taking into account the limitations of using tissue biopsies, cell‐free microRNAs (cf‐miRNAs),[1](#cas14199-bib-0001){ref-type="ref"} cell‐free DNA (cfDNA),[7](#cas14199-bib-0007){ref-type="ref"} cell‐free long non‐coding RNAs (cf‐lncRNAs),[8](#cas14199-bib-0008){ref-type="ref"}, [9](#cas14199-bib-0009){ref-type="ref"} and circulating tumor cells (CTC)[10](#cas14199-bib-0010){ref-type="ref"} that can be detected in liquid biopsies may provide a facile approach to obtain information on tissue‐specific histology, stage, and metastatic status of the tumors.[2](#cas14199-bib-0002){ref-type="ref"}, [3](#cas14199-bib-0003){ref-type="ref"}, [11](#cas14199-bib-0011){ref-type="ref"} Such an approach would provide a non‐invasive, cost‐effective procedure that has the potential to improve overall disease management. Therefore, liquid biopsy is greatly explored in current oncology research due to its minimally invasive approach for early cancer detection and for responses to cancer treatment.[3](#cas14199-bib-0003){ref-type="ref"}, [12](#cas14199-bib-0012){ref-type="ref"}

Circulating or cf‐miRNAs disseminate from tumor tissue into the peripheral circulation[1](#cas14199-bib-0001){ref-type="ref"} and are present in all body fluids, including whole blood, plasma, serum, sputum, saliva, urine, and cerebrospinal fluids.[2](#cas14199-bib-0002){ref-type="ref"}, [13](#cas14199-bib-0013){ref-type="ref"} These miRNAs are stable under harsh conditions, such as extreme pH, temperature, multiple freeze‐thaw cycles, long‐term storage, and even against RNase degradation.[14](#cas14199-bib-0014){ref-type="ref"} In addition, they have the potential to serve as biomarkers for the diagnosis, staging, progression, and prognosis of cancer.[15](#cas14199-bib-0015){ref-type="ref"} This is evident from several published reports that have shown the use of circulating miRNAs in early cancer detection, such as miR‐196a in gastric cancer,[16](#cas14199-bib-0016){ref-type="ref"} and the diagnostic roles of miR‐106b‐3p, miR‐101‐3p, and miR‐1246 in hepatocellular carcinoma.[17](#cas14199-bib-0017){ref-type="ref"} In lung cancer, low expression of the circulating miRNA‐34 family was associated with clinicopathological status and poor progression‐free and overall survival of NSCLC patients.[18](#cas14199-bib-0018){ref-type="ref"} miR‐223, miR‐20a, miR‐448, and miR‐145, as serum/plasma miRNA signatures, have shown high sensitivity (\>80%), whereas another panel including miR‐628‐3p, miR‐29c, miR‐210, and miR‐1244 have shown high specificity (\>90%) to stage I‐II NSCLC samples.[19](#cas14199-bib-0019){ref-type="ref"} Although several circulating miRNAs have been found to be associated with NSCLC, to date, their functional relevance in NSCLC has not been well characterized. Thus, a better understanding of the cellular functions of circulating miRNAs in NSCLC is warranted and may inform treatment responses.[2](#cas14199-bib-0002){ref-type="ref"} Further, delineating their biological functions could prove pivotal in the clinical development of new liquid biopsy approaches in NSCLC.

With this goal in mind, the present study investigated circulating miR‐590‐5p dysregulation in blood plasma samples of NSCLC patients compared to non‐cancerous healthy control plasma samples. miR‐590‐5p has been found to be dysregulated in various other cancers, such as colorectal,[20](#cas14199-bib-0020){ref-type="ref"}, [21](#cas14199-bib-0021){ref-type="ref"}, [22](#cas14199-bib-0022){ref-type="ref"} hepatocellular,[23](#cas14199-bib-0023){ref-type="ref"}, [24](#cas14199-bib-0024){ref-type="ref"}, [25](#cas14199-bib-0025){ref-type="ref"} breast,[26](#cas14199-bib-0026){ref-type="ref"}, [27](#cas14199-bib-0027){ref-type="ref"} cervix,[28](#cas14199-bib-0028){ref-type="ref"} vulvar,[29](#cas14199-bib-0029){ref-type="ref"} renal,[30](#cas14199-bib-0030){ref-type="ref"}, [31](#cas14199-bib-0031){ref-type="ref"} and gastric,[32](#cas14199-bib-0032){ref-type="ref"}, [33](#cas14199-bib-0033){ref-type="ref"} among others, and has been reported as both oncogenic and/or tumor suppressive. However, a role for circulating miR‐590‐5p dysregulation in lung cancer is not yet known; thus, we aimed to study its profile in NSCLC plasma samples and its clinical relevance. Additionally, we validated its target molecules, which take part in NSCLC progression and metastasis through activation of various cancer‐associated pathways.

2. MATERIALS AND METHODS {#cas14199-sec-0002}
========================

2.1. Clinical sample and data collection {#cas14199-sec-0003}
----------------------------------------

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee at the Regional Cancer Centre, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India and the Central University of Punjab, Bathinda, India. The blood samples from NSCLC patients and healthy individuals as controls were collected, and signed informed written consent was obtained from all the participants enrolled in the study. Each participant was assigned a unique code to maintain confidentiality of their information which was used only for the purposes of research.

Between July 2013 and July 2015, peripheral blood was collected from 80 patients diagnosed with NSCLC and 80 healthy individuals as controls following the inclusion and exclusion criteria. Only those patients who had not started treatment were enrolled in this study. Follow up of all the enrolled patients was done either by telephone or in person by the outpatient department of the hospital.

2.2. Characteristics of participants {#cas14199-sec-0004}
------------------------------------

Non‐small cell lung cancer patients were diagnosed based on histopathological examination of tissue biopsies according to the UICC and American Joint Committee on Cancer (AJCC) TNM staging 7th edition. Inclusion criteria for selection of NSCLC patients for the study included: (i) patients solely diagnosed with NSCLC before starting their treatment; (ii) histopathological stage confirmation as early or metastatic, adenocarcinoma or squamous cell carcinoma; (iii) patients' tumor grade between IA and IV; (iv) aged 18 years or above, and their gender information; (v) lifestyle history; number of pack‐years (packs per day × years smoked) for current or former smokers (those who have quit smoking), non‐smoker/passive smoker, and whether or not they consume alcohol and/or chew tobacco. Exclusion criteria for all NSCLC patients : (i) previous history or currently suffering from any disease; and (ii) currently taking medications.

Similarly, healthy individuals as controls with no history of cancer or other diseases were enrolled in the study. Inclusion criteria for selection of healthy individuals included: (i) individuals aged 18 years or above, and their gender information; (ii) lifestyle history; non‐smoker, non‐alcoholic, non‐tobacco chewer. Exclusion criteria for such individuals: (i) previous cancer or any other disease history; (ii) currently taking medications. Clinical characteristics of the participants in this study are listed in Table [1](#cas14199-tbl-0001){ref-type="table"}.

###### 

Clinico‐pathological features

  Characteristics           No. of NSCLC patients (N = 80)   No. of healthy controls (N = 80)   *P*‐value
  ------------------------- -------------------------------- ---------------------------------- -----------
  TNM staging                                                                                   
  II                        19                               0                                  
  III                       54                               0                                  
  IV                        7                                0                                  
  NSCLC types                                                                                   
  Adenocarcinoma            18                               0                                  
  Squamous cell carcinoma   41                               0                                  
  Mixed                     21                               0                                  
  Lymph node metastasis                                                                         
  Positive                  56                               0                                  
  Negative                  24                               0                                  
  Smoking status                                                                                
  Yes                       75                               0                                  
  No                        5                                0                                  
  Alcoholic status                                                                              
  Yes                       52                               0                                  
  No                        28                               0                                  
  Age                                                                                           
  ≥50 y                     67                               48                                 \<.0001
  \<50 y                    13                               32                                 .1148
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2.3. Circulating miRNA isolation, cDNA synthesis and qRT‐PCR assay {#cas14199-sec-0005}
------------------------------------------------------------------

Circulating miRNAs were isolated using the miRNeasy Serum/Plasma Kit (cat. no. 217184; Qiagen Inc.) as previously described.[34](#cas14199-bib-0034){ref-type="ref"} Concentration of the isolated circulating miRNAs was assessed by using a NanoDrop 2000 UV‐Vis Spectrophotometer (Thermo Fisher Scientific) and the samples were stored at −80°C until further use.

The cDNA of isolated circulating miRNA samples was synthesized using the miScript II RT Kit (cat. no. 218161; Qiagen Inc.) as described previously.[35](#cas14199-bib-0035){ref-type="ref"} These synthesized cDNAs were used as templates with which to carry out quantitative real‐time PCR (qRT‐PCR) reactions using the miScript SYBR Green PCR Kit (Qiagen Inc.) on a Bio‐Rad CFX96 thermal cycler (Hercules). qRT‐PCR reaction mixture (12.5 μL) was used for a miR‐590‐5p primer (cat. no. MS00004900; Qiagen Inc.) and a Spike‐In control cel‐miR‐39 primer (cat. no. MS00019789; Qiagen Inc.) to determine technical variability in the samples. A non‐template control reaction for each primer was also carried out to check for contamination by including all components except for the cDNA template. Conditions of qRT‐PCR, including melt curves, were followed according to the manufacturer\'s instructions. Threshold cycle (Ct) value for each sample with both primers was recorded for statistical analysis. Gene expression of all the samples was calculated using the 2^−ΔCt^ method[36](#cas14199-bib-0036){ref-type="ref"} where ΔCt = sample\'s average Ct value for miR‐590‐5p -- sample\'s average Ct value for cel‐miR‐39. All reactions were repeated at least three independent times.

2.4. Cell culture and transfection {#cas14199-sec-0006}
----------------------------------

Human NSCLC cell line, A549, was provided as a generous gift by Dr. Jayant (CDRI, India) and cultured in complete RPMI 1640 medium (Gibco, Thermo Fisher Scientific), supplemented with 10% FBS (Gibco, Thermo Fisher Scientific) and 1% PenStrep (Gibco, Thermo Fisher Scientific). All cells were maintained and incubated at 37°C in 5.0% CO~2~ in a well‐humidified incubator and were regularly checked for any type of contamination, whereas no *Mycoplasma* testing was done. For transfection, \~500 × 10^3^ cells were cultured in six‐well plates before 24 hours and miR‐590‐5p mimic (cat. no. MSY0003258) (200 mol L^‐1^) or miR‐590‐5p inhibitor (cat. no. MIN0003258) (5 mol L^‐1^) (Qiagen Inc.) was transfected with 4 μL Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific) in 500 μL Opti‐MEM reduced serum media (Gibco, Thermo Fisher Scientific) to the respective well in the plates. For vehicle control, 4 μL Lipofectamine 3000 in 500 μL Opti‐MEM reduced serum media was transfected in respective wells. Plates were incubated at 37°C in 5.0% CO~2~ for 4 hours after transfection and then supplemented with 1.5 mL complete media, further incubated for 24 hours, 48 hours, and 72 hours for the subsequent experiments.

2.5. Cell proliferation assay {#cas14199-sec-0007}
-----------------------------

Cells (6 × 10^3^/well) were seeded in 96‐well plates. After 24 hours of incubation, each well was transfected with either miR‐590‐5p mimic or inhibitor at different concentrations (between 0 and 200 mol L^‐1^) or vehicle control in Opti‐MEM reduced serum media for 24‐, 48‐ and 72‐hour time points. MTT assay (Molecular Probes, Thermo Fisher Scientific) was carried out by measuring the absorbance at 570 nm using a BioTek Synergy H1 Hybrid Reader. The experiment was repeated at least three times. Data were expressed as the percentage of viable cells using the formula: relative cell viability (%) = (average absorbance (Abs.) of transfected cells/average Abs. of vehicle control transfected cells) × 100.

2.6. Cell migration assay {#cas14199-sec-0008}
-------------------------

After transfection with either the miR‐590‐5p mimic (200 mol L^‐1^), inhibitor (5 mol L^‐1^), or vehicle control in 70 μL Opti‐MEM reduced serum media, 3.5 × 10^5^ cells were seeded into each well of Culture‐Insert 2 wells (Ibidi) placed in a respective μ‐Dish (Ibidi). The insert was removed after cell attachment to obtain a 500‐μm gap. Migration distance of the cells in the insert area was observed under an inverted microscope (Olympus) at 0 hours, 24 hours, and 48 hours until the gap was completely occupied by the migrating cells. Several different focuses were randomly selected at 4X magnification and photographed.

2.7. Cell invasion assay {#cas14199-sec-0009}
------------------------

Cell invasion assays were carried out by using a CytoSelect Cell Invasion Assay kit (Cell Biolabs, Inc.) with polycarbonate membrane inserts (pore size, 8.0 μm) for A549 cells transfected with either miR‐590‐5p mimic (200 mol L^‐1^), inhibitor (5 mol L^‐1^), or vehicle control according to the manufacturer\'s protocol. After 48 h, invasive cells were observed under 10X magnification with an inverted microscope (Olympus). Relative numbers of invasive cells after extraction from the inserts were quantified at 560 nm using the BioTek Synergy H1 Hybrid Reader. The experiments were repeated independently in triplicates.

2.8. Cell cycle assay {#cas14199-sec-0010}
---------------------

A549 cells (500 × 10^3^) were transfected with either the miR‐590‐5p mimic (200 mol L^‐1^), the inhibitor (5 mol L^‐1^), or vehicle control and harvested 48 hours post‐transfection. The cell pellet was then fixed in 70% ice‐cold ethanol and incubated at 4°C for 24 hours. After incubation, the cells were stained with FxCycle PI/RNase Staining Solution (Invitrogen, Thermo Fisher Scientific, USA) according to the manufacturer\'s protocol. Samples were analyzed with an Accuri C6 flow cytometer (BD Biosciences and analyzed using its supplied software.

2.9. Cell apoptosis assay {#cas14199-sec-0011}
-------------------------

A549 cells (500 × 10^3^) were transfected either with miR‐590‐5p mimic (200 mol L^‐1^), the inhibitor (5 mol L^‐1^), or vehicle control and were incubated for 48 hours. After transfection and incubation, the cells were scraped and pelleted with their respective transfection media. The obtained pellet was washed three times in ice‐cold 1X PBS. After washing, the cell pellet was resuspended in 500 μL of 1X Binding Buffer supplemented with the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen) and further processed according to the manufacturer\'s protocol. The samples were analyzed using an Accuri C6 (BD Biosciences) flow cytometer, equipped with software. Cells were discriminated into viable, early apoptotic, late apoptotic, and dead cells.

2.10. Target gene prediction and pathway enrichment analysis {#cas14199-sec-0012}
------------------------------------------------------------

Online available computational algorithms, TargetScan version 7.2, DIANA‐microT version 4, PITA, and miRDB, were used to identify the predicted targets of miR‐590‐5p. TarBase version 8 was used to confirm predicted targets with no previous experimental validation with respect to miR‐590‐5p.

2.11. Immunoblot assay {#cas14199-sec-0013}
----------------------

Cell lysates were prepared from A549 cells and A549 cells transfected with miR‐590‐5p mimic (200 mol L^‐1^), miR‐590‐5p inhibitor (5 mol L^‐1^) or vector control. Approximately 20 μg protein extract was separated by 10% SDS‐PAGE and transferred onto PVDF membranes (Bio‐Rad Laboratories) using the Trans‐Blot Turbo Transfer system (Bio‐Rad Laboratories). Blots were incubated with primary antibodies in 1:1000 dilutions and incubated overnight at 4°C on an orbital shaker against anti‐STAT3 (cat. no. S5933), anti‐pSTAT3 (pSer727) (cat. no. SAB4300034), anti‐Bcl‐2 (cat. no. SAB4500003), anti‐cMyc (cat. no. S4503662), anti‐Cyclin D1 (cat. no. C7464) from Sigma‐Aldrich; anti‐Caspase 3 (cat. no. 9662), anti‐Vimentin (cat. no. 5741), anti‐β‐catenin (cat. no. 8480), anti‐Snail (cat. no. 3879), anti‐TCF8/ZEB1 (cat. no. 3396), anti‐E‐cadherin (cat. no. 3195), anti‐Claudin‐1 (cat. no. 13255) and anti‐Zo‐1 (cat. no. 8193) from Cell Signaling Technologies. Anti‐β‐actin (cat. no. 4970; Cell Signaling Technologies) at a dilution of 1:3000 was used as a normalization and technical control. Blots were also incubated with HRP‐conjugated secondary antibodies that were either anti‐rabbit IgG (cat. no. 170‐6515; Bio‐Rad Laboratories) or anti‐mouse IgG (cat. no. 170‐6516; Bio‐Rad Laboratories) at dilutions of 1:5000 and were imaged using Clarity Western ECL Substrate (Bio‐Rad Laboratories) according to the manufacturer\'s instructions on a ChemiDoc Imaging System (Bio‐Rad Laboratories) using ImageLab software (Bio‐Rad Laboratories). Bands were quantified using ImageJ software (NIH).

2.12. Immunohistochemistry {#cas14199-sec-0014}
--------------------------

Formalin‐fixed paraffin‐embedded tumor tissue sections were immunostained with primary antibodies, including anti‐STAT3 (1:50), anti‐pSTAT3 (pSer727) (1:50), anti‐Cyclin D1 (1:50) and anti‐Vimentin (1:20), anti‐β‐catenin (1:50), anti‐Snail (1:20; cat. no. 3879), anti‐TCF8/ZEB1 (1:50), anti‐E‐cadherin (1:50). Immunohistochemistry experiments were carried out as previously described.[37](#cas14199-bib-0037){ref-type="ref"} Immunostained positivity was defined and classified according to the respective protein expression in either the nucleus only, cytoplasm only, cell membrane only and/or combined; blindly confirmed by the pathologist. Microscopic images were processed using a Nikon microscope. Intensity score (IS) and proportion score (PS) was evaluated according to Cappuzzo et al.[38](#cas14199-bib-0038){ref-type="ref"} For statistical analysis, total scores ranging between 0 and 200 were considered low expression, whereas those between 201 and 400 were considered high expression.

2.13. Dual‐luciferase reporter assay {#cas14199-sec-0015}
------------------------------------

For the dual‐luciferase reporter assay, the 3′‐UTR sequence of STAT3 (NM_003150) (cat. no. SC218770) containing the predicted binding sites for miR‐590‐5p and its corresponding mutated sequence (cat. no. CW304411) were cloned downstream of the *Renilla* luciferase gene in the vector pMirTarget named WT‐3′‐UTR STAT3 and MUT‐3′UTR STAT3, respectively. These vectors along with pMirTarget expression vector (cat. no. PS100062) were purchased from Origene Technologies. Using Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific), HEK293T cells were cotransfected with reporter plasmids and miR‐590‐5p mimics (200 mol L^‐1^), or a negative control. Luciferase activity was determined after 48 hours incubation using the Dual‐Luciferase Reporter Assay System (cat. no. E1910; Promega) and GloMax 20/20 luminometer (cat. no. E5311; Promega). HEK‐293T cells were subjected to dual‐luciferase activity by normalizing with *Renilla* luciferase activity according to the manufacturer\'s instructions. Normalized data were measured as the ratio of experimental (*Renilla*) luciferase to control (Firefly) luciferase. Each experiment was repeated at least three times.

2.14. Statistical analysis {#cas14199-sec-0016}
--------------------------

All statistical analyses were carried out using GraphPad Prism software 7.0. Data are presented as either mean ± standard deviation (SD) or mean ± standard error mean (SEM). Overall survival was evaluated by the Kaplan‐Meier method with a log‐rank test for comparison between miR‐590‐5p high‐expression and low‐expression groups. "High" and "low" expression was based on the median value of miR‐590‐5p expression, which was used as the cut‐off value. *P *≤ .05 was considered statistically significant.

3. RESULTS {#cas14199-sec-0017}
==========

3.1. Circulating miR‐590‐5p expression negatively correlates with NSCLC pathogenesis {#cas14199-sec-0018}
------------------------------------------------------------------------------------

A total of 80 NSCLC patients were enrolled in this study. The NSCLC cohort (n = 80) consisted of individuals with a median age of 55 ± 14.95 years in the range 40‐70 years, and an age‐matched healthy control cohort (n = 80) with a median age of 50.50 ± 15.50 years in the range 34‐66 years. Within the NSCLC cohort, study subjects were segregated on the basis of their staging; for example, stage II (n = 19) 23.75% with a median age of 56 ± 13.10 years, stage III (n = 54) 67.5% with a median age of 52 ± 12.90 years, and stage IV (n = 7) 8.75% with a median age of 64 ± 5.70 years.

Previous studies have found dysregulation of miR‐590‐5p in a number of different types of cancer cells.[20](#cas14199-bib-0020){ref-type="ref"}, [21](#cas14199-bib-0021){ref-type="ref"}, [22](#cas14199-bib-0022){ref-type="ref"}, [24](#cas14199-bib-0024){ref-type="ref"}, [26](#cas14199-bib-0026){ref-type="ref"}, [27](#cas14199-bib-0027){ref-type="ref"}, [28](#cas14199-bib-0028){ref-type="ref"}, [29](#cas14199-bib-0029){ref-type="ref"}, [31](#cas14199-bib-0031){ref-type="ref"}, [33](#cas14199-bib-0033){ref-type="ref"} Thus, we examined the correlation of miRNA with disease progression of NSCLC. We compared the levels of circulating miR‐590‐5p in plasma samples from NSCLC patients and healthy controls and found that the average expression level of circulating miR‐590‐5p was significantly downregulated (\~7.5‐fold) (*P * \< .0001; 95% CI: 0.4151‐1.077) in blood plasma samples of NSCLC patients compared to healthy controls (Figure [1](#cas14199-fig-0001){ref-type="fig"}), suggesting a negative correlation of miR‐590‐5p with NSCLC disease progression.

![Circulating microRNA (miR)‐590‐5p expression levels in plasma samples were downregulated in non‐small cell lung cancer (NSCLC) patients compared to healthy controls. Scatter plot represents normalized 2^−ΔCt^ values of individual samples from n = 3 independent qRT‐PCR experiments. Data are expressed as mean ± SD. \*\*\*\**P *\<* *.0001 calculated using an unpaired *t* test](CAS-111-826-g001){#cas14199-fig-0001}

3.2. Low expression of circulating miR‐590‐5p is associated with clinicopathological features and poor prognosis of NSCLC patients {#cas14199-sec-0019}
----------------------------------------------------------------------------------------------------------------------------------

Considering the significant downregulation of circulating miR‐590‐5p expression levels in plasma samples of NSCLC patients compared to healthy controls, we evaluated the correlation between miR‐590‐5p expression and clinicopathological features such as age, smoking history, lymph node metastasis, and TNM staging. Among different NSCLC stages, patients with TNM stage II (n = 19) showed significant downregulation of miR‐590‐5p (\~10‐fold) (*P *=* *.0306; 95% CI: 0.07404‐1.476) compared to healthy controls, whereas stage III (n = 54) NSCLC patients showed the most significant downregulation by approximately seven‐fold (*P *=* *.0005; 95% CI: 0.3332‐1.148) (Figure [2](#cas14199-fig-0002){ref-type="fig"}A). Patients with stage IV (n = 7) also showed a marginal downregulation compared to healthy controls, (Figure [2](#cas14199-fig-0002){ref-type="fig"}A). When we compared the expression levels of miR‐590‐5p among various TNM staging of NSCLC patients, no significant changes were observed between stages, suggesting that circulating miR‐590‐5p was expressed at similar levels in all NSCLC stages. Next, we analyzed the expression levels of miR‐590‐5p on the basis of NSCLC type, and we found that significant downregulation (\~9‐fold) occurred in squamous cell carcinoma (n = 41; *P *=* *.0014; 95% CI: 0.3045‐1.231), an approximate six‐fold downregulation in adenocarcinoma (n = 18; *P *=* *.0459; 95% CI: 0.01318‐1.416), and an approximate sevenfold downregulation in the mixed‐type NSCLC (n = 21, *P *=* *.0276; 95% CI: 0.08239‐1.381) (Figure [2](#cas14199-fig-0002){ref-type="fig"}B). As all groups were similarly downregulated, we did not observe any significant differences in expression between the various NSCLC types studied. NSCLC patients with both lymph node‐positive (n = 56) and ‐negative (n = 24) NSCLC showed significant downregulation of miR‐590‐5p, where lymph node‐positive patients showed an approximate seven‐fold change (*P *=* *.0003; 95% CI: 0.3447‐1.130) and lymph node‐negative patients showed an approximate nine‐fold change (*P *=* *.0137; 95% CI: 0.1604‐1.374) compared to healthy controls (Figure [2](#cas14199-fig-0002){ref-type="fig"}C).

![Circulating microRNA (miR‐590‐5p) expression correlated with clinicopathological features of non‐small cell lung cancer (NSCLC) patients. A, TNM stages of NSCLC patients. B, NSCLC histological types. C, Lymph node status of NSCLC patients. D, Smoking status of NSCLC patients. E, Alcoholic status of NSCLC patients. F, Age of NSCLC patients. G, Kaplan‐Meier survival test to determine relationships between levels of miR‐590‐5p expression and percentage of overall survival of NSCLC patients. Bar graph represents normalized 2^−ΔCt^ values from three independent experiments. Data are expressed as mean ± SEM. \**P *\<* *.05, \*\**P *\<* *.01, \*\*\**P *\<* *.001, \*\*\*\**P *\<* *.0001 calculated using unpaired *t* tests. ADC, adenocarcinoma; SCC, squamous cell carcinoma](CAS-111-826-g002){#cas14199-fig-0002}

miR‐590‐5p expression levels were also reduced significantly in NSCLC patient with smoking habits (n = 75; *P *\<* *.0001; 95% CI: 0.4093‐1.093), whereas no significant changes were observed statistically in non‐smokers compared to healthy controls (Figure [2](#cas14199-fig-0002){ref-type="fig"}D). Similarly, miR‐590‐5p expression levels were significantly reduced in alcoholic patients (n = 52; *P *=* *.0003; 95% CI: 0.3675‐1.189) along with non‐alcoholic patients (n = 28; *P *=* *.0170; 95% CI: 0.1251‐1.249) (Figure [2](#cas14199-fig-0002){ref-type="fig"}E). Patients over 50 years showed significant downregulation of miR‐590‐5p by approximately nine‐fold (n = 67; *P * \< .0001; 95% CI: 0.4009‐1.124), whereas no statistically significant change (*P* = .1148) was seen in patients below 50 years compared to healthy controls (Figure [2](#cas14199-fig-0002){ref-type="fig"}F). Taken together, the above data suggested that the expression levels of miR‐590‐5p negatively correlated with various clinicopathological features of NSCLC patients, including smoking and alcohol history.

To further investigate the association of miRNA‐590‐5p expression with prognosis of NSCLC patients, Kaplan‐Meier and log‐rank analyses were used to evaluate the effects of miR‐590‐5p expression on overall patient survival. We found that patients with low miR‐590‐5p expression had significantly lower median survival rates in comparison to patients expressing high miR‐590‐5p levels (*P *\<* *.0001; 95% CI: 1.412‐3.498) (Figure [2](#cas14199-fig-0002){ref-type="fig"}G). Together, these findings identified a negative correlation of miR‐590‐5p in the prognosis of NSCLC patients, and suggested that miR‐590‐5p may function as a tumor suppressor in NSCLC development.

3.3. MicroRNA‐590‐5p inhibits NSCLC cell proliferation and affects cell cycle progression and apoptosis {#cas14199-sec-0020}
-------------------------------------------------------------------------------------------------------

A characteristic hallmark of many cancer cells is their uncontrolled cell proliferation and resistance to apoptotic signals. On the basis of the results mentioned above, we further assessed how miR‐590‐5p might regulate cell proliferation and apoptosis in lung tumor cells. To this purpose, we transfected human A549 adenocarcinoma lung cancer cells with either a miR‐590‐5p inhibitor (5 mol L^‐1^) or a miR‐590‐5p mimic (200 mol L^‐1^) as mentioned in the Materials and Methods. By using MTT assays, we observed that A549 cells transfected with the inhibitor showed an \~70% increase in viability, whereas those treated with the mimic showed an \~60% decrease in viability 48 hours post‐transfection (Figure [3](#cas14199-fig-0003){ref-type="fig"}A). Further, through colony formation assays, we detected an increase in both size and number of colonies in the A549 cells transfected with the inhibitor, and the opposite for the mimic‐transfected A549 cells compared to the vehicle control (Figure [3](#cas14199-fig-0003){ref-type="fig"}B). Taken together, the results from both assays indicated that miR‐590‐5p decreased growth and proliferation of A549 cells. As the maximum changes were observed at 48 hours post‐transfection, this time point was used for subsequent assays.

![MicroRNA (miR)‐590‐5p inhibits non‐small cell lung cancer (NSCLC) cell proliferation and affects cell cycle progression and apoptosis, as assessed by transfecting miR‐590‐5p inhibitor and mimics in A549 cells. A, Cell proliferation was assessed by MTT assays at 24‐, 48‐, and 72‐h time points in A549 cells transfected with vehicle control, an miR‐590‐5p inhibitor (5 mol L^-1^), or a miR‐590‐5p mimic (200 mol L^-1^). B, Colony formation assay for A549 cells transfected with vehicle control, inhibitor (5 mol L^-1^), or mimic (200 mol L^-1^). C, Cell cycle analysis was carried out by flow cytometry of A549 cells transfected with vehicle control, inhibitor (5 mol L^-1^), or mimic (200 mol L^-1^). D, Apoptosis was assessed by flow cytometry of A549 cells transfected with vehicle control, inhibitor (5 mol L^-1^), or mimic (200 mol L^-1^). E, A549 cells were transfected with vehicle control, inhibitor (5 mol L^-1^), or mimic (200 mol L^-1^) to determine normalized protein levels of Cyclin D1, Bcl‐2 and Caspase 3 as assessed by immunoblotting. All experiments were carried out three independent times. Values and bar graphs are presented as mean ± SEM where \**P *\>* *.05, \*\**P *\<* *.05 represent significant differences from vehicle control calculated using paired *t* tests. F, Immunohistochemistry shows brown‐stained positive tumor cells in the nucleus, the cytoplasm, and/or the cell membrane, representing protein levels of Cyclin D1 in NSCLC patient tissues. Scale bar, 100 μm and n = 3 NSCLC tissues](CAS-111-826-g003){#cas14199-fig-0003}

We next evaluated the influence of miR‐590‐5p on cell cycle regulation. Cell cycle analyses showed significant cell cycle arrest in A549 cells harboring high levels of miR‐590‐5p. In contrast, depletion of miR‐590‐5p caused an accumulation of these cells in the S and G2/M phases, and significantly reduced the number of cells in the G0/G1 phase by \~61% (Figure [3](#cas14199-fig-0003){ref-type="fig"}C). Further, increased levels of miR‐590‐5p in the A549 cells treated with the mimic resulted in increased cell death compared to cells containing lower levels of this miRNA (Figure [3](#cas14199-fig-0003){ref-type="fig"}D), which was further evident by changes in the levels of both anti‐ and pro‐apoptotic factors (Figure [3](#cas14199-fig-0003){ref-type="fig"}E), and Cyclin D1 (Figure [3](#cas14199-fig-0003){ref-type="fig"}F). Consistent with these findings, immunohistochemistry (IHC) analysis of NSCLC patient tissue samples also showed Cyclin D1 positivity (Figure [3](#cas14199-fig-0003){ref-type="fig"}E,F) in as much as 60% of the tumor cells. Taken together, these results suggested that miR‐590‐5p played a role in NSCLC suppression by inhibiting cell growth and inducing apoptosis.

3.4. MicroRNA‐590‐5p influences multistage carcinogenic programming in tumor cells {#cas14199-sec-0021}
----------------------------------------------------------------------------------

Cell migration and invasion are crucial for cancer progression and, based on the results above, we expected a correlation of miR‐590‐5p with these processes. Thus, we assessed the influence of miR‐590‐5p on cell migration and invasive potential of A549 cells. Results showed increased migration of cells transfected with the inhibitor, whereas lower levels of cell migration were observed when transfected with the mimic, compared to the A549 control and vehicle control cells (Figure [4](#cas14199-fig-0004){ref-type="fig"}A). Similarly, when miR‐590‐5p was depleted, more cells (\~3‐fold) were able to invade the matrix and polycarbonate membranes after 48 hours compared to the control cells (Figure [4](#cas14199-fig-0004){ref-type="fig"}B).

![MicroRNA (miR)‐590‐5p influences cell migration, invasion, and epithelial‐mesenchymal transition (EMT). A, Cell migration assays were carried out with A549 cells transfected with vehicle control, an inhibitor, or a mimic at 0‐, 24‐, and 48‐h time points. B, Cell invasion capacity of A549 cells was assessed in cells transfected with vehicle control, inhibitor, or a mimic at 48 h after transfection. All experiments were carried out three independent times. Values and bar graphs are presented as mean ± SEM where \**P *\>* *.01, \*\**P *\<* *.001 represent significant differences from vehicle control calculated using paired *t* tests. C, A549 cells were transfected with vehicle control, an inhibitor (5 mol L^-1^), or a mimic (200 mol L^-1^) to measure normalized protein levels of EMT‐regulated proteins: Vimentin, β‐catenin, TCF8/ZEB1, Snail, E‐cadherin, Claudin‐1, Zo‐1 as assessed by immunoblotting. All experiments were carried out four independent times where values and bar graphs represent mean ± SEM. \**P *\>* *.05, \*\**P *\<* *.05 represent significant differences from vehicle control calculated using paired *t* tests. D, Immunohistochemistry shows brown‐stained positive tumor cells in the nucleus (N), cytoplasm (C), and/or cell membrane (M), representing protein levels of β‐catenin, Vimentin, E‐cadherin, Snail, and TCF8/ZEB1 in non‐small cell lung cancer (NSCLC) patient tissues. Scale bar, 100 μm and n = 3 NSCLC tissues](CAS-111-826-g004){#cas14199-fig-0004}

Results from the experiments described above suggested that miR‐590‐5p influenced the processes of migration and invasion of NSCLC cells. In order to substantiate this, we analyzed the impact of temporal changes of miR‐590‐5p levels with the epithelial‐to‐mesenchymal transition (EMT), which plays a critical role in cancer progression. Indeed, depletion of miR‐590‐5p resulted in increased protein levels of the mesenchymal markers, Vimentin, Snail, TCF8/ZEB1, and β‐catenin by \~65%, 40%, 85% and 66%, respectively, whereas its overexpression significantly increased the levels of epithelial markers, such as E‐cadherin, Zo‐1, and Claudin‐1 by \~100%, \~60%, and \~50%, respectively, compared to the vehicle control‐treated cells. As expected, increased levels of miR‐590‐5p had an opposite effect on the levels of these proteins (Figure [4](#cas14199-fig-0004){ref-type="fig"}C). Thus, these results suggested that miR‐590‐5p modulated the invasion and migration of tumor cells through EMT pathways. IHC analysis of EMT proteins in NSCLC patient tumor samples showed that a significant proportion of the tumor cells were positive for various proteins, such as β‐catenin (78%); Snail (96%), TCF8/ZEB1 (72%), and E‐cadherin (85%) (Figure [4](#cas14199-fig-0004){ref-type="fig"}D), thus supporting the involvement of these proteins in NSCLC progression.

3.5. *STAT3* is a direct target of miR‐590‐5p {#cas14199-sec-0022}
---------------------------------------------

MicroRNAs function by binding and regulating their target protein‐coding RNAs, which can function as oncogenes or tumor suppressors. Therefore, to gain insight into the molecular mechanisms of miR‐590‐5p in the progression of NSCLC, publicly available algorithms were used to predict its possible targets. TargetScan, DIANA‐microT, PITA and miRDB predicted 70 common possible targets, analyzed by Venny 2.1 ( <http://bioinfogp.cnb.csic.es/tools/venny>/) (Figure [5](#cas14199-fig-0005){ref-type="fig"}A). From the list of predicted target mRNA molecules, *STAT3* was identified as one of its potential targets, binding at its 3′UTR (Figure [5](#cas14199-fig-0005){ref-type="fig"}B). It is well known that STAT3 plays a significant role in the progression of lung cancer, and has also been found to be a key protein in NSCLC through the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Therefore, to verify whether miR‐590‐5p directly regulated *STAT3*, we carried out a dual‐luciferase reporter assay and found that the miR‐590‐5p mimic (200 mol L^‐1^) significantly inhibited (\~55%, *P *\<* *.05) luciferase activity in HEK293T cells transfected with the pMirTarget WT‐3′UTR STAT3 reporter plasmid compared to control cells transfected with an empty vector (Figure [5](#cas14199-fig-0005){ref-type="fig"}C). As expected, the activity remained unaffected in the HEK293T cells transfected with the pMirTarget MUT‐3′UTR STAT3 mutated plasmid (Figure [5](#cas14199-fig-0005){ref-type="fig"}C). Thus, these results indicated that *STAT3* is a direct target of miR‐590‐5p.

![*STAT3* is a target of microRNA (miR)‐590‐5p in non‐small cell lung cancer (NSCLC) cells. A, In silico target prediction of miR‐590‐5p. Seventy common targets of miR‐590‐5p (highlighted by a black circle) resulted from different databases: TargetScan version 7.2 (blue), DIANA micro‐T (pink), PITA (green), and miRDB (peach). B, Predicted miR‐590‐5p binding sites with the 3′UTR of *STAT3* as assessed by the online bioinformatics tool DIANA micro‐T. C, Detection of miR‐590‐5p regulation of *STAT3* using a dual‐luciferase reporter assay. Data are shown as mean ± SEM of triplicate experiments, where \**P* \> .05, \*\**P* \< .05 represent significant difference calculated using paired *t* tests. NC, negative control](CAS-111-826-g005){#cas14199-fig-0005}

To determine the effect of miR‐590‐5p on STAT3, both total STAT3 and phosphorylated STAT3 (pSTAT3 at Ser727) protein levels were assessed by immunoblotting. Notably, in the miR‐590‐5p inhibitor‐transfected A549 cells, expression levels of both STAT3 and pSTAT3 increased by \~45% and \~55%, respectively, whereas both were decreased by \~40% when A549 cells were transfected with its mimic compared to A549 control and vehicle control cells after 48 hours (Figure [6](#cas14199-fig-0006){ref-type="fig"}A). These results suggested a negative correlation of miR‐590‐5p with STAT3 protein in NSCLC cells, consistent with our results showing that \~90% of tumor cells were positive for STAT3 in the cytoplasm, and \~82% of the tumor cells were positive for pSTAT3 in both the nucleus and cytoplasm (Figure [6](#cas14199-fig-0006){ref-type="fig"}B).

![Regulation of STAT3 and its downstream targets by microRNA (miR)‐590‐5p. A, Immunoblot assays were used to determine normalized protein levels of STAT3, Phospho‐STAT3 (pSTAT3^pSer727^) and c‐Myc in A549 cells, and A549 cells transfected with vehicle control, a miR‐590‐5p inhibitor (5 mol L^-1^), or a miR‐590‐5p mimic (200 mol L^-1^). All experiments were carried out four independent times where values and bar graphs represent mean ± SEM. \**P *\>* *.05, \*\**P *\<* *.05 represent significant differences from vehicle control calculated using paired *t* tests. B, Immunohistochemistry shows brown‐stained positive tumor cells in the nucleus, the cytoplasm, and/or both, representing protein levels of STAT3 and pSTAT3 in NSCLC patient tissues. Scale bar, 100 μm and n = 3 NSCLC tissues](CAS-111-826-g006){#cas14199-fig-0006}

Because we found an effect of miR‐590‐5p in regulating *STAT3*, we also examined its effects on two STAT3 downstream targets, *Cyclin D1* and *c‐Myc*, which also play roles in cell proliferation and cell cycle progression. We studied the effects of miR‐590‐5p suppression and overexpression on the protein levels of these two downstream targets of STAT3, and found that they were upregulated when A549 cells were transfected with its inhibitor, and downregulated when transfected with its mimic, similar to the STAT3 and pSTAT3 protein levels (Figures [3](#cas14199-fig-0003){ref-type="fig"}E and [6](#cas14199-fig-0006){ref-type="fig"}A). Moreover, IHC analysis also showed high expression of Cyclin D1 in NSCLC patient tissue samples (Figure [3](#cas14199-fig-0003){ref-type="fig"}F).

4. DISCUSSION {#cas14199-sec-0023}
=============

Recently, cellular miR‐590‐5p has been shown to play important roles in tumorigenesis and metastasis of various cancers where it was shown to function as either a tumor suppressor or an oncomiR based on its target(s) in the respective cancers. Its expression was found to be downregulated in breast, hepatocellular, colorectal, and lung cancer tissues, and targeted the Wnt/β‐catenin pathway, SOX2 (SRY‐box 2), TGF‐βRII (transforming growth factor beta receptor 2),[23](#cas14199-bib-0023){ref-type="ref"} NF90/VEGFA (nuclear factor 90/vascular endothelial growth factor A)[20](#cas14199-bib-0020){ref-type="ref"}, [21](#cas14199-bib-0021){ref-type="ref"} and GAB1 (GRB2 associated binding protein A)[39](#cas14199-bib-0039){ref-type="ref"} which promote cancer growth and progression.[22](#cas14199-bib-0022){ref-type="ref"}, [26](#cas14199-bib-0026){ref-type="ref"}, [27](#cas14199-bib-0027){ref-type="ref"}, [40](#cas14199-bib-0040){ref-type="ref"}, [41](#cas14199-bib-0041){ref-type="ref"} Likewise, miR‐590‐5p oncogenic properties were reported in gastric, cervical, vulvar, and clear cell renal cancer, where it targets RECK (reversion inducing cysteine rich protein with kazal motifs),[32](#cas14199-bib-0032){ref-type="ref"} CHL1 (close homolog of L1),[28](#cas14199-bib-0028){ref-type="ref"} TGF‐βRII,[29](#cas14199-bib-0029){ref-type="ref"} and PBRM1 (Polybromo 1),[30](#cas14199-bib-0030){ref-type="ref"} respectively, and regulates cell proliferation, migration and invasion of cancer cells. However, the role of circulating miR‐590‐5p in blood plasma has not been reported. Herein, we observed that circulating miR‐590‐5p was downregulated (\~7.5‐fold) in NSCLC patient plasma samples which correlated with their clinicopathological features, whereas its upregulation reflected prolonged survival over its low expression levels.

Mechanistically, we showed *STAT3* as a direct downstream target gene of miR‐590‐5p. STAT3 is a transcription factor known to regulate various cellular signaling pathways involved in cancer progression.[42](#cas14199-bib-0042){ref-type="ref"} In NSCLC, upregulated transcripts and protein levels of STAT3 were reported to be associated with lymph node metastasis,[43](#cas14199-bib-0043){ref-type="ref"} poor prognosis,[28](#cas14199-bib-0028){ref-type="ref"}, [44](#cas14199-bib-0044){ref-type="ref"} tumor differentiation,[44](#cas14199-bib-0044){ref-type="ref"} and downregulation of miR‐124.[45](#cas14199-bib-0045){ref-type="ref"} miR‐590‐5p showed an inverse correlation with constitutive STAT3 and phosphorylated STAT3 in the present study, and highlighted the significance of miR‐590‐5p in STAT3‐dependent tumor progression. As STAT3 pathways constituting signaling networks are important for tumor progression, our results suggest that the miR‐590‐5p‐STAT3 axis may function as a signaling pathway by which miR‐590‐5p could influence tumor growth. Various proteins such as interleukin (IL)‐6, JAK1/2, epidermal growth factor receptor (EGFR), and Src directly activate STAT3 and phosphorylate it at Tyr705. Studies have also shown that phosphorylation of STAT3 at Ser727, present in its transactivating C‐terminal domain,[46](#cas14199-bib-0046){ref-type="ref"} enhances the constitutive phosphorylation of STAT3 at Tyr705 in both the nucleus and the cytoplasm. pSTAT3 at Ser727 has also been reported to increase its DNA‐binding ability, and thereby control transcriptional activity of cancerous cells[47](#cas14199-bib-0047){ref-type="ref"}, [48](#cas14199-bib-0048){ref-type="ref"} and activate other downstream targets, such as *Cyclin D1*,[44](#cas14199-bib-0044){ref-type="ref"} *Bcl‐2*,*c‐Myc*,*Vimentin*,*TCF8/ZEB1*, etc. that regulate oncogenic pathways.[49](#cas14199-bib-0049){ref-type="ref"} In line with this, we observed a negative correlation of miR‐590‐5p levels with increased Cyclin D1, Bcl‐2 and decreased Caspase 3 protein levels (Figure [3](#cas14199-fig-0003){ref-type="fig"}E) in miR‐590‐5p inhibitor‐transfected A549 cells. Similarly, c‐Myc protein levels were upregulated upon inhibiting endogenous miR‐590‐5p levels (Figure [6](#cas14199-fig-0006){ref-type="fig"}A), along with increased cellular proliferation (Figure [3](#cas14199-fig-0003){ref-type="fig"}A,B).

Another important factor in cancer progression is an EMT phenotype,[50](#cas14199-bib-0050){ref-type="ref"} which is critical for tumor metastasis. Increasing evidence has suggested that STAT3 is responsible for the occurrence and metastasis of cancer involving the regulation of EMT[51](#cas14199-bib-0051){ref-type="ref"} through its activation by IL‐17 and TGF‐β.[52](#cas14199-bib-0052){ref-type="ref"}, [53](#cas14199-bib-0053){ref-type="ref"} Along these lines, an inverse correlation of circulating miR‐590‐5p levels with EMT regulatory protein such as Vimentin, TCF8/ZEB1, β‐catenin, and Snail1 of mesenchymal origin was found. Moreover, we detected decreased levels of E‐cadherin, Claudin‐1 and Zo‐1 in NSCLC patient tissue samples reflecting the migration and invasion potential of NSCLC cells. Thus, downregulation of circulating miR‐590‐5p increased EMT, perhaps by upregulation of *STAT3*, thereby promoting NSCLC progression.

In summary, we showed that circulating miR‐590‐5p functions as a tumor suppressor in NSCLC by regulating various hallmarks of cancer, such as cell proliferation, migration, invasion, apoptosis, and EMT (Figure [7](#cas14199-fig-0007){ref-type="fig"}). Thus, determining the circulating levels of miR‐590‐5p could potentially be used as a diagnostic marker for NSCLC, which might prove to be a potential target in NSCLC management. Further investigations with additional patient samples may provide further support for circulating miR‐590‐5p as a biomarker for improved diagnosis, prognosis, and as a potential therapeutic target for NSCLC patients.

![Schematic diagram of various cancer hallmarks and molecules regulated by microRNA (miR)‐590‐5p in non‐small cell lung cancer. Various upregulated and downregulated molecules and pathways are depicted by up and down arrows, respectively. ECM, extracellular matrix; EMT, epithelial‐to‐mesenchymal transition](CAS-111-826-g007){#cas14199-fig-0007}
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